Abstract
BackgroundOsteopontin is a marker for breast cancer progression, which in previous studies has also been associated with resistance to certain anti-cancer therapies. It is not known which splice variants may mediate treatment resistance.MethodsHere we analyze the association of osteopontin variant expression before treatment, differentiated according to immunohistochemistry with antibodies to exon 4 and to the osteopontin-c splice junction respectively, with the ensuing therapy responses in 119 Polish breast cancer patients who presented between 1995 and 2008.ResultsWe found from Cox hazard models, logrank test and Wilcoxon test that osteopontin exon 4 was associated with a favorable response to tamoxifen, but a poor response to chemotherapy with CMF (cyclophosphamide, methotrexate, fluorouracil). Osteopontin-c is prognostic, but falls short of being a significant predictor for sensitivity to treatment.ConclusionsThe addition of osteopontin splice variant immunohistochemistry to standard pathology work-ups has the potential to aid decision making in breast cancer treatment.
Highlights
Osteopontin is a marker for breast cancer progression, which in previous studies has been associated with resistance to certain anti-cancer therapies
Predictive markers provide upfront information regarding how likely a patient is to benefit from a specific treatment, and may guide the choice from available therapies
Relevant predictive markers mostly belong to the groups of drug targets, molecules associated with drug transport or metabolism, and
Summary
Osteopontin is a marker for breast cancer progression, which in previous studies has been associated with resistance to certain anti-cancer therapies. It is not known which splice variants may mediate treatment resistance. Prognostic markers allow forecasts regarding the natural course of the disease. They differentiate between patients likely to have a good versus a poor outcome. Predictive markers provide upfront information regarding how likely a patient is to benefit from a specific treatment, and may guide the choice from available therapies. Relevant predictive markers mostly belong to the groups of drug targets, molecules associated with drug transport or metabolism, and
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
